Exhibit 107
Calculation of Filing Fee Tables
Form S-1
(Form Type)
InMed Pharmaceuticals Inc.
(Exact Name of Registrant as Specified in its Charter)
| | Security Type | | Security Class Title | | Fee Calculation or Carry Forward Rule | | Amount Registered(1)(3) | | | Proposed Maximum Offering Price Per Unit(2) | | | Maximum Aggregate Offering Price(2) | | | Fee Rate | | | Amount of Registration Fee | |
Fees to Be Paid | | Equity | | common shares, no par value | | 457(c) | | | 3,000,000 | | | $ | 4.325 | | | $ | 12,975,000 | | | | 0.00015310 | | | $ | 1,986.47 | |
| | Total Offering Amounts | | | | | | | $ | 12,975,000 | | | | | | | $ | 1,986.47 | |
| | Total Fees Previously Paid | | | | | | | | | | | | | | | — | |
| | Total Fee Offsets | | | | | | | | | | | | | | | | — | |
| | | | | | Net Fee Due | | | | | | | | | | | | | | | $ | 1,986.47 | |
(1) | In accordance with Rule 416 under the Securities Act of 1933, as amended, or the Securities Act, the Registration Statement also covers an indeterminate number of additional common shares that may be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. |
| |
(2) | Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) under the Securities Act, based upon the average of the high and low prices of the registrant’s common shares as reported on the Nasdaq Capital Market on December 20, 2024. |
| |
(3) | Represents common shares that may be issued pursuant to that certain Standby Equity Purchase Agreement, dated December 13, 2024, entered into by the registrant and YA II PN, LTD. |